Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary Researchers see gene-therapy grant improving vision
Researchers see gene-therapy grant improving vision July 24, 2013 - The University of Florida’s ophthalmology department, together with gene therapy company AGTC in Alachua, received an $8.4 million grant from the National Eye Institute at the National Institutes of Health to study gene therapy for
View HTML
Toggle Summary The University of Florida and AGTC Secure $8.4M Grant to Study Rare Eye Disease
Funds will be used to develop a gene therapy treatment for Achromatopsia in both animal models and human clinical trials
View HTML
Toggle Summary The Alpha-1 Project announces first investment in potential treatment for Alpha-1 Antitrypsin Deficiency, major emphysema genetic risk factor
Applied Genetic Technologies Corporation to conduct clinical trials
View HTML
Toggle Summary AGTC Secures $37.5 Million Series B Funding
Clinical stage gene therapy company will use financing, led by Alta Partners and S.R. One, to fund studies for the treatments of rare human diseases
View HTML
Toggle Summary AGTC Receives Grant from the Foundation Fighting Blindness for Pre-Clinical Study of Gene Therapy for Eye Disease
Pre-clinical trial in animal models tests ability to deliver sustainable treatment in patients with X-Linked Retinoschisis (XLRS) using proprietary AAV gene delivery technology.
View HTML
Toggle Summary AGTC Receives Second Grant from Food and Drug Administration for Clinical Study of Genetic Respiratory Disease
Ongoing Phase II Trial tests ability to deliver sustainable treatment in patients with Alpha 1 Antitrypsin Deficiency (AAT) using proprietary AAV technology.
View HTML
Toggle Summary AGTC Receives Grant from Food and Drug Administration for Clinical Study of Genetic Retinal Disease
Ongoing Phase II Trial tests ability to deliver sustainable treatment in patients with Leber congenital amaurosis (LCA) using proprietary AAV technology.
View HTML
Toggle Summary Bellingham brothers get experimental gene therapy in attempt to save their sight
Bellingham brothers get experimental gene therapy in attempt to save their sight When 11-year-old Casey Catalan goes on a walk in his Bellingham neighborhood, he hustles to be home before twilight. Once the sun fades, so does Casey's vision, because of a congenital eye disease.
View HTML
Toggle Summary AGTC and Icagen Announce Technology Transfer Agreement
AGTC and Icagen Announce Technology Transfer Agreement June 24, 2010 – AGTC, a privately held company, and Icagen, Inc. (NASDAQ: ICGN) today announced the completion of an agreement for the purchase and sale of certain patent rights between the companies.  Icagen is transferring its rights to
View HTML
Toggle Summary AGTC and National Neurovision Research Institute Collaborate, Funding Research in two Genetic Retinal Diseases
AGTC and National Neurovision Research Institute Collaborate, Funding Research in two Genetic Retinal Diseases Combined Funds and Resources to be used to further demonstrate the AGTC’s AAV system’s ability to deliver sustainable treatments for human retinal diseases.
View HTML
Visionary science for life changing cures.